Public Services and Procurement Canada, the Public Health Agency of Canada, Health Canada and Innovation, Science and Economic Development Canada are working together, along with the COVID-19 Vaccine and Therapeutics Task Forces, towards procurement and deployment of COVID-19 vaccines and related supplies.
The Government of Canada has now signed agreements with the following companies to obtain vaccines:
- Sanofi and GSK, which will supply up to 72 million of doses of their COVID-19 adjuvanted recombinant protein-based vaccine candidate.
- Johnson & Johnson, which will supply up to 38 million doses of its vaccine candidate, Ad26.COV2.S.
- Novavax, which will supply up to 76 million doses of its vaccine candidate, NVX-CoV2373.
- Pfizer, which will supply a minimum of 20 million doses of its mRNA-based vaccine candidate, BNT162. The government is negotiating with the company to have the agreement include options for obtaining additional doses.
- Moderna, which will supply up to 56 million doses of its vaccine candidate, mRNA-1273.
The Government of Canada will continue to negotiate and sign other agreements with leading pharmaceutical companies to ensure the supply of potential vaccines in Canada.
To date, the Government of Canada has allocated $1 billion for the five agreements that are in place. This includes some upfront payments that the pharmaceutical companies require to support vaccine development, testing and at-risk manufacturing.
This investment guarantees Canada’s earliest possible place in production runs.
Subsequent payments are contingent on the vaccines passing clinical trials and obtaining regulatory approval. All contracts Canada signs with vaccine developers contain off-ramps and exit provisions should they be required.